President Trump has recently indicated his plans to implement a 200% tariff on pharmaceuticals. If this move goes forward to encourage drug manufacturing in the U.S., it could significantly worsen medical debt for many Americans who are already facing difficulties managing healthcare expenses.
According to data, a large percentage of Americans are dependent on prescribed medications. Over 60% of adults fill at least one prescription each year.
This reliance increases with age. The CDC notes that nine out of ten individuals over 65 depend on these medications for long-term health.
Many adults acknowledge that they avoid taking medicine due to cost concerns. Almost half of those over 50 skip filling prescriptions because of the expense or uncertainty about who offers better pricing, as reported by research from the Kaiser Family Foundation.
Prescription drug prices in the U.S. are approximately three times higher than those in other countries, making the U.S. the most expensive for these medications, as highlighted by the Department of Health and Human Services.
This high pricing is partially due to the fact that numerous widely-used drugs in the U.S. are imported.
Drug imports have surged in recent years, increasing from $65 billion in 2006 to $151 billion in 2019. Many of these medications treat conditions like rheumatoid arthritis, osteoporosis, cancer, schizophrenia, and obesity, as noted in an article by CFR.
The ultimate aim of enhancing domestic drug manufacturing is to reduce reliance on foreign supply, lower medication costs, and improve access. Nevertheless, the strategies employed to reach this goal must be carefully assessed so as not to create short-term price increases or shortages that can severely impact many individuals.
Trump mentioned that his proposed customs approach will not take effect for at least a year. There have been signals that tariffs might initially be lower, potentially increasing to “very high tariffs” over time.
Experts have raised concerns about the ramifications these tariffs might have on public health, arguing that they may not be adequate to develop the necessary infrastructure to balance supply and demand effectively.
According to Afsane Beschloss from Rock Creek Group, “We need those medicines, so it’s going to be potentially disastrous for everyone, and those companies will take a long time to produce them here in the U.S.” in response to Trump’s tariff plan.
UBS analysts are closely monitoring Trump’s initial proposal to postpone the enforcement of the 200% tariffs by a year, suggesting that the timeline is too short for pharmaceutical companies to relocate manufacturing. They believe a timeline of four to five years is more realistic.
Moreover, a study commissioned by the pharmaceutical industry group Phrma indicated that even a 25% tariff could result in a nearly $51 billion increase in U.S. drug prices.
Trump’s tariff plans could particularly harm individuals who rely on essential medications. About 80% of commonly used pills and tablets in the U.S. are sourced from abroad.
A Brookings analysis indicated that due to the low margins on generic prescriptions, tariffs could force some medications—often the most affordable options for many—out of the market.
Last year, Americans accrued approximately $220 billion in medical debt, with $10 million surpassing $1,000, and $3 million exceeding $10,000.
Adding billions more in drug costs due to these tariffs risks exacerbating existing financial pressures, potentially leading to shortages of critical treatments and worsening access to necessary medications for individuals who cannot already manage their expenses.
Trump’s policies predominantly affect the elderly, disabled, and marginalized groups, communities that indeed require reasonable access to prescription drugs.
It has taken decades for drug manufacturing in the U.S. to diminish; reversing this trend cannot happen overnight. Vulnerable populations need a well-considered policy approach, rather than hasty decisions that could push them into deeper financial trouble to obtain already unaffordable medications.
